Lv7
4980 积分 2021-12-28 加入
Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?
10分钟前
待确认
NeoADAURA: Can We Afford to Overlook Objective Response Rates?
13分钟前
待确认
Longitudinal analysis of circulating tumor DNA and CA19-9 dynamics in predicting disease relapse and monitoring treatment response in stage I–III pancreatic ductal adenocarcinoma: An interim analysis of a prospective observational study
2个月前
已完结
Postoperative Circulating Tumour DNA in Predicting Recurrence of Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis
2个月前
已完结
Comparison of circulating tumor DNA assays for molecular residual disease detection in non-small cell lung cancer
2个月前
已完结
Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes
3个月前
已完结
The Genomic Landscape of Breast Cancer in Young and Older Women
3个月前
已完结
Distantly metastatic differentiated thyroid carcinoma is kinase‐driven and enriched for DNA repair and DNA methylation gene alterations
4个月前
已完结
Prognostic Value of MammaPrint in Diverse Populations: Evaluating Racial Disparities in Breast Cancer Outcomes
5个月前
已关闭
Potential of Minimal Residual Disease in Guiding Adjuvant Therapy Decisions in Non–Small Cell Lung Cancer
6个月前
已关闭